Sign In
Buy DVAX
$15.50
+0 (+0%)
At Close: May 08, 2026
Dynavax Announces Second Quarter 2020 Financial Results
08:02pm, Thursday, 06'th Aug 2020
* Second quarter 2020 HEPLISAV-B® net product revenue of $2.4 million * Multiple new CpG 1018 collaborations established to develop novel adjuvanted vaccine candidates across several indications,
Return On Capital Employed Overview: Dynavax Technologies
03:56pm, Wednesday, 05'th Aug 2020
Dynavax Technologies (NASDAQ: DVAX) reported Q1 sales of $10.92 million. Earnings fell to a loss of $19.31 million, resulting in a 29.49% decrease from last quarter. Dynavax Technologies collected $10
Why Dynavax's Stock Is Trading Higher Today
07:53pm, Monday, 03'rd Aug 2020
Dynavax Technologies (NASDAQ: DVAX) shares are trading higher on Monday after the company announced it will sell its SD-101 oncology program to TriSalus Life Sciences in a purchase agreement for up to
* SD-101 is a proprietary investigational, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide * TriSalus plans to further develop SD-101 as an oncology therapeu
Dynavax to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020
08:05pm, Thursday, 30'th Jul 2020
EMERYVILLE, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report
Will Dynavax Technologies (DVAX) Report Negative Q2 Earnings? What You Should Know
04:33pm, Wednesday, 29'th Jul 2020
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coronavirus Vaccine Development Puts These Stocks in Focus
12:19pm, Tuesday, 28'th Jul 2020
Moderna and Pfizer launches two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year.
Is a Beat in Store for Dynavax (DVAX) This Earnings Season?
02:53pm, Monday, 27'th Jul 2020
Dynavax (DVAX) is actively pursuing development of coronavirus vaccine through collaborations. Investors are likely to focus on progress of vaccine programs on Q2 earnings call.
So far Sunday, July 26, NASDAQ is up 0.33% and the S&P is down -0.11%. Here are this morning’s most
Dynavax Technologies (DVAX) Stock Moves -0.3%: What You Should Know
09:50pm, Thursday, 23'rd Jul 2020
Dynavax Technologies (DVAX) closed the most recent trading day at $10.12, moving -0.3% from the previous trading session.
Dynavax and Medigen Announce Collaboration to Develop a Novel Adjuvanted COVID-19 Vaccine Candidate
12:00pm, Thursday, 23'rd Jul 2020
* Collaboration focused on developing an adjuvanted COVID-19 vaccine using Medigen’s subunit vaccine candidate with Dynavax’s CpG 1018 * In preclinical testing, the combination generated strong v
So far Wednesday, July 22, NASDAQ is down -4.97% and the S&P is down -1.44%. Here are this morning’s most
William Blair Reiterates Buy Rating for Dynavax Technologies (NASDAQ:DVAX)
03:18am, Wednesday, 22'nd Jul 2020
Dynavax Technologies (NASDAQ:DVAX)‘s stock had its “buy” rating reaffirmed by equities researchers at William Blair in a research note issued on Tuesday, TipRanks reports. Other analysts have al
Dynavax Announces the Appointment of Two New Board Members
08:10pm, Tuesday, 21'st Jul 2020
Ms. Julie Eastland, a strategic and financial executive with over 25 years of experience in biotechnology companiesMr. Brent MacGregor, a senior executive with over 20 years of.
So far Sunday, July 19, NASDAQ is down -1.01% and the S&P is down -0.16%. Let’s take a look at
